Explore

Trendline Trendline
Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins
Trendline Trendline
Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch
Trendline Trendline
CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development
Trendline Trendline
Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success
Trendline Trendline
NeoGenomics to Engage with Investors at Upcoming Conferences, Highlighting Oncology Diagnostics

NeoGenomics to Engage with Investors at Upcoming Conferences, Highlighting Oncology Diagnostics

NeoGenomics to Engage with Investors at Upcoming Conferences, Highlighting Oncology Diagnostics
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress
Trendline Trendline
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026